# GWPCARE2 A Study to Investigate the Efficacy and Safety of Cannabidiol (GWP42003-P) in Children and Young Adults With Dravet Syndrome

> **NCT02224703** · PHASE3 · COMPLETED · sponsor: **Jazz Pharmaceuticals** · enrollment: 199 (actual)

## Conditions studied

- Epilepsy
- Dravet Syndrome

## Interventions

- **DRUG:** GWP42003-P
- **DRUG:** Placebo Control

## Key facts

- **NCT ID:** NCT02224703
- **Lead sponsor:** Jazz Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-04-13
- **Primary completion:** 2018-04-09
- **Final completion:** 2018-04-09
- **Target enrollment:** 199 (ACTUAL)
- **Last updated:** 2022-09-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02224703

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02224703, "GWPCARE2 A Study to Investigate the Efficacy and Safety of Cannabidiol (GWP42003-P) in Children and Young Adults With Dravet Syndrome". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT02224703. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*